rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    TRVI
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Trevi Therapeutics director Michael Heffernan sells $595,805 in stock
      Nov 12Investing.comTRVI
      Does Wider Losses Change The Bull Case For Trevi Therapeutics Stock (TRVI)?
      Nov 10Yahoo FinanceTRVI
      Trevi Therapeutics, Inc. Q3 2026 Earnings Call Summary
      Nov 10Yahoo FinanceTRVI
      Trevi Therapeutics Inc (TRVI) Q3 2026 Earnings Call Highlights: Strong Cash Position, FDA ...

      Trevi Therapeutics Inc (TRVI) outlines a cash runway into 2030, positive FDA feedback for non-IPF ILD, and a clear path to potential first-in-class status in chronic cough indications.

      Nov 10Yahoo FinanceTRVI
      What Trevi Therapeutics (TRVI) Said on Its Q3 Earnings Call
      Nov 9Yahoo FinanceTRVI
      Trevi Therapeutics Q3 2026 Earnings Call Transcript
      Nov 9BenzingaTRVI
      Trevi Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
      Nov 9Yahoo FinanceTRVI
      Trevi Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 9, 2026
      Nov 2Yahoo FinanceTRVI
      Trevi Therapeutics (TRVI) Stock May Still Look Expensive Against Book Value
      Nov 1Yahoo FinanceTRVI
      Trevi Therapeutics to Participate in Stifel's 2026 Healthcare Conference
      Oct 27Yahoo FinanceTRVI
      Do Trevi Therapeutics’ (TRVI) CORAL Data and GSK’s Exit Reframe Its Chronic Cough Ambitions?
      Oct 13Yahoo FinanceTRVI
      Trevi Therapeutics Announces Oral Presentation Accepted at the CHEST 2026 Annual Meeting
      Oct 13Yahoo FinanceTRVI
      Trevi Therapeutics Q2 2026 Earnings Call Transcript - Trevi Therapeutics (NASDAQ:TRVI)

      Trevi Therapeutics (NASDAQ:TRVI) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to

      Oct 12BenzingaTRVI
      BMO reiterates Trevi Therapeutics stock rating after rival study fails
      Oct 7Investing.comTRVI
      Oppenheimer reiterates Trevi Therapeutics stock rating ahead of trial update
      Sep 25Investing.comTRVI
      Trevi Therapeutics' Sample Size Re-estimation for Chronic Cough Trial Likely Positive, Oppenheimer Says
      Sep 25Yahoo FinanceTRVI
      Trevi Therapeutics (TRVI) Receives a Buy from H.C. Wainwright

      Detailed price information for Trevi Therapeutics Inc (TRVI-Q) from The Globe and Mail including charting and trades.

      Sep 22The Globe and MailTRVI
      Trevi Therapeutics Insider Sold Shares Worth $595,806, According to a Recent SEC Filing
      Sep 17Yahoo FinanceTRVI
      Trevi Therapeutics at cantor global healthcare conference: central cough bet
      Sep 11Investing.comTRVI
      Trevi Therapeutics (TRVI) Stock Trades At A Premium To Fair Value
      Sep 5Yahoo FinanceTRVI
      Trevi Therapeutics to Participate in Upcoming September Conferences

      NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will participate in the following conferences in September. 2026 Cantor Global He

      Sep 3Yahoo FinanceTESTTRVI
      Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026

      Professor Marlies Wijsenbeek will give an oral presentation on the quality-of-life outcomes assessed by the LCQ from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough Dr. Imran Satia will give a poster presentation on the quality-of-life outcomes assessed by the LCQ from the Phase 2a RIVER trial of nalbuphine ER for the treatment of patients with RCC NEW HAVEN, Conn., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a

      Aug 26Yahoo FinanceTRVI

      This is the newest page. Registered accounts read further back.